Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



Bristol-Myers Squibb Makes Significant Progress in Psoriatic Arthritis Treatment

December 29, 2024
Bristol-Myers Squibb Company, a leading pharmaceutical company, has announced promising results from two Phase 3 trials evaluating the effectiveness of its new drug, Sotyktu deucravacitinib, in treating psoriatic arthritis in adults. The trials have shown that Sotyktu hits key endpoints and provides positive outcomes for patients suffering from this debilitating condition. Institutional investors have taken notice of the positive results, with 78% of them investing in Bristol-Myers Squibb. The company's stock, traded under the symbol BMY on NYSE, has been gaining attention in the market. Although this news makes Bristol-Myers Squibb an appealing investment opportunity, it is recommended to seek guidance from professionals at Stocks Prognosis to assess the future movement of the company's stock.

Find out how the BRISTOL-MYERS SQUIBB COMPANY rate is expected to change

Get Forecast for BMY

Investor opinions & comments:

This could be a game-changer for psoriatic arthritis patients. I'm considering investing in Bristol-Myers Squibb
— from MilaWagner at 01-01-2025 19:29
I'm not sure I'm ready to invest in Bristol-Myers Squibb just yet. I'll wait for more data on Sotyktu
— from JessicaHall at 01-01-2025 08:10
This is great news for psoriatic arthritis patients! Can't wait to see this drug on the market
— from CashCharlie at 12-31-2024 19:54
Great to see Bristol-Myers Squibb making progress in treating psoriatic arthritis
— from JamesThomas at 12-31-2024 19:15
I wonder if the positive outcomes will hold up in further trials. It's still too early to tell
— from LilyPerez at 12-31-2024 12:59
I've been looking for new treatments for psoriatic arthritis. Excited to learn more about Sotyktu
— from JeremiahSnyder at 12-31-2024 00:19
I hope this drug can provide relief for psoriatic arthritis sufferers. I'll definitely keep an eye on Bristol-Myers Squibb
— from KatherineSanchez at 12-30-2024 20:37
Investors seem confident in Bristol-Myers Squibb. The stock is definitely worth considering
— from WyattRiley at 12-30-2024 20:27
I've been looking for new treatments for psoriatic arthritis. Excited to learn more about Sotyktu
— from StockSamantha at 12-30-2024 12:59
While the results are promising, we should be cautious until more information is available
— from AdamWells at 12-29-2024 20:48
I hope this drug can provide relief for psoriatic arthritis sufferers. I'll definitely keep an eye on Bristol-Myers Squibb
— from SamanthaEvans at 12-29-2024 18:56
This is great news for psoriatic arthritis patients! Can't wait to see this drug on the market
— from MoneyMartha at 12-29-2024 17:40
Promising results from the Phase 3 trials! This could be a breakthrough for psoriatic arthritis treatment
— from DavidWilson at 12-29-2024 15:18
If you want to leave a comment, then you need Login or Register





Other news for BMY

BMYJune 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu  ~1 min.

Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....

BMYMay 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit  ~2 min.

QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....

BMYMay 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin  ~2 min.

On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....

BMYMay 8, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target as QuantWave Forecast Achieves 7.55% Profit  ~1 min.

BRISTOL-MYERS SQUIBB COMPANY has seen its stock reach the predicted price target set by QuantWave's automated forecasting platform....

BMYApril 10, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Forecast Target with 8.57% Profit: A Success Story for QuantWave  ~2 min.

BRISTOL-MYERS SQUIBB COMPANY (BMY) recently reached the price target forecasted by QuantWave, resulting in a profitable outcome for investors....



Related news

BMYDecember 29, 2024Bristol Myers Squibb: Promising Results from Phase 3 Psoriatic Arthritis Trials  ~1 min.

Bristol Myers Squibb (BMY) recently announced positive topline results from its Phase 3 trials evaluating Sotyktu deucravacitinib in adults with psoriatic arthritis....

BMYDecember 26, 2024Positive Results from Psoriatic Arthritis Trials Boost Bristol-Myers Squibb Stock  ~1 min.

Bristol-Myers Squibb Company (BMY), a leading pharmaceutical company, has recently announced positive topline results from two pivotal Phase 3 trials evaluating its drug Sotyktu deucravacitinib in adults with psoriatic arthritis. The trials have shown promising outcomes, with the drug meeting key endpoints and demonstrating effectiveness in treating the condition. Psoriatic arthritis is a chronic ...

VRTXMarch 22, 2025Vertex Pharmaceuticals VRTX: One of the Best Biotech Stocks to Buy According to Billionaires  ~2 min.

Vertex Pharmaceuticals Incorporated (VRTX) has been recognized as one of the top biotech stocks to invest in by billionaires....

REGNJanuary 3, 2025Regeneron Pharmaceuticals: A Promising Future with Strong Returns  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making waves in the pharmaceutical industry with its groundbreaking research and innovative treatments....

VRTXJanuary 12, 2025Vertex Pharmaceuticals Incorporated Faces Setbacks in Clinical Trials  ~1 min.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares experienced a slide recently due to setbacks in its clinical trials....